Matches in SemOpenAlex for { <https://semopenalex.org/work/W1518930887> ?p ?o ?g. }
- W1518930887 abstract "Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10% to 15% of non‐squamous tumours. This subtype is more common in women than men and is less associated with smoking. Objectives To assess the clinical effectiveness of single ‐agent or combination EGFR therapies used in the first‐line treatment of people with locally advanced or metastatic EGFR M+ NSCLC compared with other cytotoxic chemotherapy (CTX) agents used alone or in combination, or best supportive care (BSC). The primary outcome was overall survival. Secondary outcomes included progression‐free survival, response rate, toxicity, and quality of life. Search methods We conducted electronic searches of the the Cochrane Register of Controlled Trials (CENTRAL) (2015, Issue 6), MEDLINE (1946 to 1 June 2015), EMBASE (1980 to 1 June 2015), and ISI Web of Science (1899 to 1 June 2015). We also searched the conference abstracts of the American Society for Clinical Oncology and the European Society for Medical Oncology (1 June 2015); Evidence Review Group submissions to the National Institute for Health and Care Excellence; and the reference lists of retrieved articles. Selection criteria Parallel randomised controlled trials comparing EGFR‐targeted agents (alone or in combination with cytotoxic agents or BSC) with cytotoxic chemotherapy (single or doublet) or BSC in chemotherapy‐naive patients with locally advanced or metastatic (stage IIIB or IV) EGFR M+ NSCLC unsuitable for treatment with curative intent. Data collection and analysis Two review authors independently identified articles, extracted data, and carried out the 'Risk of bias' assessment. We conducted meta‐analyses using a fixed‐effect model unless there was substantial heterogeneity, in which case we also performed a random‐effects analysis as a sensitivity analysis. Main results Nineteen trials met the inclusion criteria. Seven of these exclusively recruited people with EGFR M+ NSCLC; the remainder recruited a mixed population and reported results for people with EGFR M+ NSCLC as subgroup analyses. The number of participants with EGFR M+ tumours totalled 2317, of whom 1700 were of Asian origin. Overall survival (OS) data showed inconsistent results between the included trials that compared EGFR‐targeted treatments against cytotoxic chemotherapy or placebo. Erlotinib was the intervention treatment used in eight trials, gefitinib in seven trials, afatinib in two trials, and cetuximab in two trials. The findings of one trial (FASTACT 2) did report a statistically significant OS gain for participants treated with erlotinib plus cytotoxic chemotherapy when compared to cytotoxic chemotherapy alone, but this result was based on a small number of participants (n = 97). For progression‐free survival (PFS), a pooled analysis of 3 trials (n = 378) demonstrated a statistically significant benefit for erlotinib compared with cytotoxic chemotherapy (hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.24 to 0.38). In a pooled analysis with 491 participants administered gefitinib, 2 trials (IPASS and NEJSG) demonstrated a statistically significant PFS benefit of gefitinib compared with cytotoxic chemotherapy (HR 0.39; 95% CI 0.32 to 0.48). Afatinib (n = 709) showed a statistically significant PFS benefit when compared with chemotherapy in a pooled analysis of 2 trials (HR 0.42; 95% CI 0.34 to 0.53). Commonly reported grade 3/4 adverse events for afatinib, erlotinib, and gefitinib monotherapy were rash and diarrhoea. Myelosuppression was consistently worse in the chemotherapy arms, fatigue and anorexia were also associated with some chemotherapies. No statistically significant PFS or OS benefit for cetuximab plus cytotoxic chemotherapy (n = 81) compared to chemotherapy alone was reported in either of the two trials. Six trials reported on quality of life and symptom improvement using different methodologies. For each of erlotinib, gefitinib, and afatinib, 2 trials showed improvement in one or more indices for the tyrosine‐kinase inhibitor (TKI) compared to chemotherapy. The quality of evidence was high for the comparisons of erlotinib and gefitinib with cytotoxic chemotherapy and for the comparison of afatinib with cytotoxic chemotherapy. Authors' conclusions Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression‐free survival compared to cytotoxic chemotherapy. We also found a beneficial effect of the TKI compared to cytotoxic chemotherapy. However, we found no increase in overall survival for the TKI when compared with standard chemotherapy. Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. There were no data supporting the use of monoclonal antibody therapy." @default.
- W1518930887 created "2016-06-24" @default.
- W1518930887 creator A5011624664 @default.
- W1518930887 creator A5026627275 @default.
- W1518930887 creator A5032242852 @default.
- W1518930887 creator A5041932491 @default.
- W1518930887 creator A5049793416 @default.
- W1518930887 creator A5054521432 @default.
- W1518930887 creator A5066990182 @default.
- W1518930887 creator A5068763092 @default.
- W1518930887 date "2016-05-25" @default.
- W1518930887 modified "2023-09-30" @default.
- W1518930887 title "First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer" @default.
- W1518930887 cites W1247968195 @default.
- W1518930887 cites W1500599576 @default.
- W1518930887 cites W1819148429 @default.
- W1518930887 cites W1822530935 @default.
- W1518930887 cites W1964238015 @default.
- W1518930887 cites W1967210184 @default.
- W1518930887 cites W1969116196 @default.
- W1518930887 cites W1975850777 @default.
- W1518930887 cites W1979332174 @default.
- W1518930887 cites W1983414823 @default.
- W1518930887 cites W1988106671 @default.
- W1518930887 cites W2010699829 @default.
- W1518930887 cites W2019236425 @default.
- W1518930887 cites W2022575295 @default.
- W1518930887 cites W2023550894 @default.
- W1518930887 cites W2026951964 @default.
- W1518930887 cites W2037139573 @default.
- W1518930887 cites W2037177568 @default.
- W1518930887 cites W2038886187 @default.
- W1518930887 cites W2041192107 @default.
- W1518930887 cites W2041436152 @default.
- W1518930887 cites W2044433401 @default.
- W1518930887 cites W2057977761 @default.
- W1518930887 cites W2059067711 @default.
- W1518930887 cites W2064415268 @default.
- W1518930887 cites W2064676228 @default.
- W1518930887 cites W2065350134 @default.
- W1518930887 cites W2076178766 @default.
- W1518930887 cites W2083674804 @default.
- W1518930887 cites W2085803274 @default.
- W1518930887 cites W2089664277 @default.
- W1518930887 cites W2093157946 @default.
- W1518930887 cites W2095618958 @default.
- W1518930887 cites W2096096763 @default.
- W1518930887 cites W2096198395 @default.
- W1518930887 cites W2096504879 @default.
- W1518930887 cites W2098301527 @default.
- W1518930887 cites W2099556905 @default.
- W1518930887 cites W2103940769 @default.
- W1518930887 cites W2104811705 @default.
- W1518930887 cites W2110023367 @default.
- W1518930887 cites W2110835998 @default.
- W1518930887 cites W2111662961 @default.
- W1518930887 cites W2112339468 @default.
- W1518930887 cites W2112474794 @default.
- W1518930887 cites W2112660136 @default.
- W1518930887 cites W2114461323 @default.
- W1518930887 cites W2116827288 @default.
- W1518930887 cites W2118135682 @default.
- W1518930887 cites W2119209952 @default.
- W1518930887 cites W2120420501 @default.
- W1518930887 cites W2124967121 @default.
- W1518930887 cites W2126251787 @default.
- W1518930887 cites W2127101185 @default.
- W1518930887 cites W2128059540 @default.
- W1518930887 cites W2128278369 @default.
- W1518930887 cites W2129360604 @default.
- W1518930887 cites W2130256619 @default.
- W1518930887 cites W2130357378 @default.
- W1518930887 cites W2131795655 @default.
- W1518930887 cites W2132157071 @default.
- W1518930887 cites W2133149289 @default.
- W1518930887 cites W2135192471 @default.
- W1518930887 cites W2135958370 @default.
- W1518930887 cites W2136601558 @default.
- W1518930887 cites W2139343412 @default.
- W1518930887 cites W2139720565 @default.
- W1518930887 cites W2139799027 @default.
- W1518930887 cites W2144330816 @default.
- W1518930887 cites W2149095868 @default.
- W1518930887 cites W2149733252 @default.
- W1518930887 cites W2152755651 @default.
- W1518930887 cites W2153048714 @default.
- W1518930887 cites W2154662831 @default.
- W1518930887 cites W2156560090 @default.
- W1518930887 cites W2160982674 @default.
- W1518930887 cites W2162246408 @default.
- W1518930887 cites W2162394887 @default.
- W1518930887 cites W2162724777 @default.
- W1518930887 cites W2165771694 @default.
- W1518930887 cites W2166084034 @default.
- W1518930887 cites W2168340462 @default.
- W1518930887 cites W2171139285 @default.
- W1518930887 cites W2185481272 @default.
- W1518930887 cites W2210071992 @default.
- W1518930887 cites W2246516047 @default.
- W1518930887 cites W2259557965 @default.